



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Optical Coherence Tomography Angiography Features in Diabetic Patients with Unexplained Visual Loss

Thesis

*Submitted for Partial Fulfillment
of Master Degree in Ophthalmology*

By

Enas Ibrahiem Abdallah Ibrahiem

M.B.B. Ch, Mansoura University

Under Supervision of

Prof. Abd AL Rahman Gaber Salman

Professor of Ophthalmology

Faculty of Medicine – Ain Shams University

Dr. Weam Mohamed Ahmed Ebeid

Assistant Professor of Ophthalmology

Faculty of Medicine – Ain Shams University

Dr. Noureldin Hussein Abozeid

Lecturer of Ophthalmology

Faculty of Medicine – Ain Shams University

Faculty of Medicine - Ain Shams University

Cairo-Egypt

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا
أَنْتَ عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Abd AL Rahman Gaber Salman**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Weam Mohamed Ahmed Ebeid**, Assistant Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Moureldin Hussein Abozeid**, Lecturer of Ophthalmology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Enas Ibrahiem Abdallah Ibrahiem

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	ii
List of Abbreviations.....	v
Introduction	- 1 -
Aim of the Work	6
Review of Literature	7
Patients and Methods.....	38
Results.....	46
Discussion	61
Summary	74
Conclusion	76
References	77
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Early Treatment Diabetic Retinopathy Study Research Group, Early Treatment Diabetic Retinopathy Study Research Group.....	10
Table 2:	Early Treatment Diabetic Retinopathy Study Research Group, Early Treatment Diabetic Retinopathy Study Research Group.....	11
Table 3:	Demographic data among the studied group.....	46
Table 4:	Type of DM, duration, IOP and Best Corrected Vision among the studied group.....	48
Table 5:	Foveal Avascular Zone and Vessel Density in FD - 300 "%" among the studied group.....	49
Table 6:	Parafoveal vessel density "%" and Parafoveal Thickness among the studied group.....	50
Table 7:	Foveal Vessel Density "%" and Foveal Thickness among the studied group.....	51
Table 8:	Diabetic macular ischemia among the studied group.....	52
Table 9:	Correlation between Best Corrected Vision LogMAR and other variables.....	54
Table 10:	Relation between Diabetic Macular Ischemia and Demographic Data	58
Table 11:	Relation between Diabetic Macular Ischemia and other variables	59

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Exudates, dot-and-blot hemorrhage, and micro aneurysms can be seen.....	10
Figure 2:	Proliferative diabetic retinopathy - advanced, uncontrolled	11
Figure 3:	Moderate non-PDR with CSME	12
Figure 4:	Non-PDR with early sign of ischemia of the fovea; (a) clinical photo (b) fluorescein angiogram	13
Figure 5:	FA of diabetic maculopathy.....	17
Figure 6:	OCTA of the retina and Histological section of the retina.....	21
Figure 7:	OCTA Features of Diabetic Maculopathy	23
Figure 8:	A 12 mm × 12 mm en face OCTA scan showing retinal neovascularization in proliferative diabetic retinopathy (upper panel, blue arrow).....	24
Figure 9:	En face OCTA scan (upper panel) demonstrates areas of diabetic macular edema (green arrow).....	25
Figure 10:	Measurement of foveal retinal thickness on the right, and FAZ area, perimeter, Acircularity Index, on the left	29
Figure 11:	OCTA parameters on a 3 × 3 mm ² (a,c) vessel density in the superficial and deep capillary plexus, (b,d) Color maps show the vessel density in superficial and deep capillary plexus	31
Figure 12:	Parafoveal Vessel Density Measurement in SCP (left) and DCP (right) using 0.5 mm and 1.5 mm rings centered on the fovea	32
Figure 13:	Motion Artifact.....	34
Figure 14:	Projection Artifact.....	35

List of Figures cont...

Fig. No.	Title	Page No.
Figure 15:	12x12 mm Wide Field OCTA, this montage allows for a comparable field to that imaged by FFA but it is still not commercially available.....	36
Figure 16:	Microaneurysm Detection by OCTA.....	37
Figure 17:	Automated FAZ parameters.....	42
Figure 18:	Automated parafoveal and foveal density in superficial plexus, Automated foveal and parafoveal retinal thickness by optical coherence tomography angiography.	43
Figure 19:	Automated parafoveal and foveal density in deep plexus by optical coherence tomography angiography.	44
Figure 20:	Optical coherence tomography angiography of the superficial capillary plexus	44
Figure 21:	Sex distribution among the studied group.	47
Figure 22:	Type of Diabetes among the studied group	48
Figure 23:	Diabetic macular ischemia among the studied group	52
Figure 24:	Scatter diagram for positive correlation between Best Corrected Vision LogMAR and age / years.	55
Figure 25:	Scatter diagram for positive correlation between Best Corrected Vision LogMAR and Foveal Avascular Zone area "mm ² ".	55
Figure 26:	Scatter diagram for positive correlation between Best Corrected Vision LogMAR and Perimeter "mm"	56
Figure 27:	Scatter diagram for positive correlation between best corrected vision and Acircularity Index.....	56

List of Figures cont...

Fig. No.	Title	Page No.
Figure 28:	Scatter diagram for positive correlation between best corrected vision and Diabetic Macular Ischemia.	57
Figure 29:	Relation between Diabetic Macular Ischemia and Age.....	58
Figure 30:	Box plot for Median Best Corrected Vision LogMAR in relation to Diabetic Macular Ischemia.	60

List of Abbreviations

Abb.	Full term
<i>AMN</i>	<i>Acute macular neuroretinopathy</i>
<i>DCP</i>	<i>Deep capillary plexus</i>
<i>DM</i>	<i>Diabetes mellitus</i>
<i>DME</i>	<i>Diabetic macular edema</i>
<i>DMI</i>	<i>Diabetic macular ischemia</i>
<i>DR</i>	<i>Diabetic retinopathy</i>
<i>ETDRS</i>	<i>Early Treatment Diabetic Retinopathy Study</i>
<i>FAZ</i>	<i>Fovea avascular zone</i>
<i>FFA</i>	<i>Fundus fluorescein angiography</i>
<i>GCL</i>	<i>Ganglion cell layer</i>
<i>ICP</i>	<i>Intermediate capillary plexus</i>
<i>ILM</i>	<i>Internal limiting membrane</i>
<i>INL</i>	<i>Inner nuclear layer</i>
<i>IR</i>	<i>Infrared</i>
<i>MacTel</i>	<i>Macular telangiectasia</i>
<i>NFL</i>	<i>Nerve fiber layer</i>
<i>NPDR</i>	<i>Non-proliferative diabetic retinopathy</i>
<i>OCT</i>	<i>Optical coherence tomography</i>
<i>OCTA</i>	<i>Optical coherence tomography angiography</i>
<i>PDR</i>	<i>Proliferative diabetic retinopathy</i>
<i>RPCP</i>	<i>Radial peripapillary capillary plexus</i>
<i>RPE</i>	<i>Retinal pigment epithelium</i>
<i>SPSS</i>	<i>Statistical Package of Social Science</i>
<i>SSADA</i>	<i>Split-spectrum amplitude decorrelation angiography</i>
<i>SVP</i>	<i>Superficial vascular plexus</i>

INTRODUCTION

Diabetes mellitus (DM) is a chronic disorder characterized by impaired metabolism of glucose due to insulin deficiency or its resistance, leading to hyperglycemia and late development of vascular and neuropathic complications. which causes multi-organ ischemic effects including diabetic retinopathy. Approximately one-third of diabetics suffer from diabetic retinopathy (DR), and one-third of DR patients have vision-threatening disease (*Lee et al., 2015*).

As a result, Diabetic retinopathy (DR) is the one of the leading causes of blindness in the working-age population in developed countries (*Cheung, 2010*). By 2035, estimates are that 592 million people will be affected by diabetes mellitus (*IDF Diabetes Atlas, 2013*). Early detection of its first signs plays a pivotal role in the management of DR, playing an important role in this significant public health issue (*Geiss et al., 2014*).

Patients with type 1 diabetes may show evidence of retinopathy as early as 5 years after the onset of diabetes and almost all patients will show varying degrees of retinopathy 20 years after the onset of diabetes. Background retinopathy may even be present at the time of diagnosis of type 2 diabetic patients, consistent with the usually long duration of subclinical hyperglycemia in such patients and more than 60% of type 2

diabetic patients will have some degree of retinopathy after 20 years of onset of diabetes.

The Early Treatment Diabetic Retinopathy Study (ETDRS) group was used to assess the severity of diabetic retinopathy. Diagnosis of DR is based on clinical findings and can be classified into early non-proliferative diabetic retinopathy (NPDR) and more advanced proliferative diabetic retinopathy (PDR) associated with retinal ischemia and development of neovascularization (*Kumar et al., 2007*).

The main sight-threatening complications of DR are diabetic maculopathy, which include diabetic macular edema (DME) and diabetic macular ischemia (DMI) (*Mohamed et al., 2007*), and complications from PDR - vitreous hemorrhage and retinal detachment (*Nentwich et al., 2015*) Digital retinal fundus image analysis has been shown to be able to detect early DR and DME in routine DR screening (*Saari et al., 2004*) while it has high sensitivity and specificity, it has been shown to have a low negative predictive value (*D'Aloisio et al., 2019*).

Diabetic macular ischemia (DMI) may occur exclusively or in association with DME. leading to visual acuity loss in diabetic patients. One study demonstrated that about 41% of DR patients had some degree of DMI (*Sim et al., 2013a*).

A lot of studies have discussed the impact the of DMI on the visual acuity function (*Tyrberg, 2008*). Furthermore, other

studies suggest that in patients receiving treatment for diabetic macular edema (DME) the coexistence of DMI may have an adverse effect on outcomes, or limits the benefits of treatments, regardless of whether the treatment consists of laser photocoagulation or intravitreal pharmacotherapies as bevacizumab (*Chung et al., 2008*) and triamcinolone (*Jonas et al., 2005*). so, patients with DMI under treatment were reported to develop neovascularization earlier than patients without DMI (*Ip et al., 2015*).

Larger prospective studies, such as ETDRS and the RESTORE study, have not demonstrated clear associations between decreased treatment benefit and increased macular ischemia (*Babiuch et al., 2019; Mitchell et al., 2011*).

These contrasting results may be related, in part, to the adoption in many studies of simplified DMI grading schemes, commonly eschewing detailed quantitative analyses of capillary loss for qualitative analysis of the FAZ (*Chung et al., 2008; Conrath et al., 2005*).

The requirement for angiography for DMI evaluation is because it has not been studied in the pivotal epidemiological studies of diabetic retinopathy (*Varma et al., 2004; Klein et al., 1992*) and, the prevalence and natural history of this condition remains unknown.